The first domestic injectable drug for the treatment of coronavirus with direct registration in Russia. It is called Areplivir and will be admitted to hospitals by the end of 2021. It is reported by TASS with reference to the statement of the developer company “Promomed”.

According to the Promomed company, full-fledged production on the basis of Biochemist JSC and deliveries to Russian hospitals will begin in December 2021.

It is noted that a multicenter clinical study of the drug under the leadership of the Russian Academy of Sciences Dmitry Pushkar confirmed the effectiveness of drugs when used in hospitals.

Earlier, the director of the Gamaleya National Research Center for Epidemiology and Microbiology, Alexander Gintsburg, said that a drug is being developed in Russia to suppress coronavirus infection.

He also announced work to create a drug from antibodies to treat patients with COVID-19. Clinical trials of the drug for patients with coronavirus will begin within three to four months.

In addition, earlier in November it became known that Russia had created its own medicine for coronavirus – innoviron, the developer of the drug was Valenta Pharm. Experts conducted the second phase of drug testing back in June. At the end of October this year, there were documents for registration of the development.

The Promomed company was the first in the world to create an injectable form of farapiravir, despite the fact that the powder does not dissolve in water. Injections are recommended as a more effective form of treatment for patients in hospitals.

Also developed “Areplivir” for oral administration, it is included in the current recommendations both for treatment at home under the supervision of doctors, and in hospitals. The final decision will be made by the Ministry of Health for the review of methodological recommendations on coronavirus.

The chief pulmonologist of the Ministry of Health, Corresponding Member of the Russian Academy of Sciences Sergei Avdeev noted that until now the only drug to be administered as an injection was a foreign agent, not only expensive, but also inaccessible. He proposes the use of a domestic antiviral agent in the form of injections, which will become widely available, may turn the tide in the fight against the coronavirus pandemic.

Earlier, the head of the Federal Biomedical Agency (FMBA) Veronika Skvortsova said that the drug against coronavirus Mir-19 is completing the second phase of clinical trials. She recalled that Mir-19 belongs to the group of etiotropic antiviral drugs. It is intended to prevent or treat COVID-19 via inhalation or intranasal administration.